Midatech's investigational glioblastoma treatment gets Fast Track status
U.S.-listed shares of Midatech Pharma PLC ADR soared 35.7% in premarket trading on Wednesday after the company said the Food and Drug Administration granted Fast Track status to the treatment it's developing for recurrent glioblastoma, a fast-growing brain tumor. Midatech's stock is down 40.3% this ...